Literature DB >> 27590416

Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis.

Jeung Hui Pyo1, Hyuk Lee1, Byung-Hoon Min1, Jun Haeng Lee1, Min Gew Choi2, Jun Ho Lee3, Tae Sung Sohn2, Jae Moon Bae2, Kyoung-Mee Kim4, Seungmin Yeon5, Sin-Ho Jung5,6, Jae J Kim1, Sung Kim2.   

Abstract

BACKGROUND: The clinicopathological features of mixed-type (MT) early gastric cancer (EGC) according to Lauren's classification remain uninvestigated. This study aimed to clarify the clinicopathological features of MT EGC, particularly in relation to lymph node metastasis (LNM) and long-term survival.
METHODS: This study included 5309 patients who underwent gastrectomy for EGC. The clinicopathological features, LNM, and long-term outcomes of patients with MT carcinomas were compared with those of patients with intestinal-type (IT) and diffuse-type (DT) cancers. Furthermore, we evaluated the predictors of LNM in each Lauren classification subgroup.
RESULTS: Patients with MT carcinomas were likelier to have larger tumors, submucosal invasion, lymphovascular invasion, and LNM than those with IT or DT carcinomas. Multivariate logistic regression analysis revealed that the Lauren classification was a significant predictor of LNM (P < 0.001). The significant predictors of LNM in MT carcinomas were female sex, greater tumor size, presence of submucosal invasion, and lymphovascular invasion. However, the overall survival of patients with MT carcinoma was not significantly different from that of patients with IT or DT carcinomas (P = 0.104).
CONCLUSIONS: The presence of MT EGC carries a higher risk of LNM compared with the presence of IT or DT carcinomas. Therefore, MT carcinomas should be managed with gastrectomy that includes lymph node dissection instead of endoscopic resection.

Entities:  

Keywords:  Early gastric cancer; Lauren’s classification; Lymph node metastasis; Mixed type

Mesh:

Year:  2016        PMID: 27590416     DOI: 10.1007/s00535-016-1254-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  22 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer.

Authors:  Jeung Hui Pyo; Cheol Min Shin; Hyuk Lee; Byung-Hoon Min; Jun Haeng Lee; Su Mi Kim; Min Gew Choi; Jun Ho Lee; Tae Sung Sohn; Jae Moon Bae; Kyung Mee Kim; Hye Seung Kim; Sin-Ho Jung; Jae J Kim; Sung Kim
Journal:  Ann Surg       Date:  2016-12       Impact factor: 12.969

4.  Long-Term Outcome of Endoscopic Resection vs. Surgery for Early Gastric Cancer: A Non-inferiority-Matched Cohort Study.

Authors:  Jeung Hui Pyo; Hyuk Lee; Byung-Hoon Min; Jun Haeng Lee; Min Gew Choi; Jun Ho Lee; Tae Sung Sohn; Jae Moon Bae; Kyung-Mee Kim; Joong Hyun Ahn; Keumhee C Carriere; Jae J Kim; Sung Kim
Journal:  Am J Gastroenterol       Date:  2016-01-19       Impact factor: 10.864

5.  Histological mixed-type as an independent prognostic factor in stage I gastric carcinoma.

Authors:  Shuhei Komatsu; Daisuke Ichikawa; Mahito Miyamae; Hiroki Shimizu; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Mitsuo Kishimoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

6.  The mixed type in Laurén's classification of gastric carcinoma. Histologic description and biologic behavior.

Authors:  S Stelzner; P Emmrich
Journal:  Gen Diagn Pathol       Date:  1997-07

Review 7.  Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value.

Authors:  Felix Berlth; Elfriede Bollschweiler; Uta Drebber; Arnulf H Hoelscher; Stefan Moenig
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

8.  Clinical outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer.

Authors:  Hae Yeon Kang; Sang Gyun Kim; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Surg Endosc       Date:  2009-07-08       Impact factor: 4.584

9.  Histological mixed-type as an independent risk factor for nodal metastasis in submucosal gastric cancer.

Authors:  Mahito Miyamae; Shuhei Komatsu; Daisuke Ichikawa; Toshiyuki Kosuga; Takeshi Kubota; Kazuma Okamoto; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Mitsuo Kishimoto; Eigo Otsuji
Journal:  Tumour Biol       Date:  2015-08-05

10.  Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas.

Authors:  Hua-chuan Zheng; Xiao-han Li; Takuo Hara; Shinji Masuda; Xiang-hong Yang; Yi-fu Guan; Yasuo Takano
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

View more
  23 in total

1.  A Risk-Scoring Model for Predicting Lymph Node Metastasis in Early Gastric Cancer Patients: a Retrospective Study and External Validation.

Authors:  Lihu Gu; Manman Chen; Parikshit Asutosh Khadaroo; Xueqiang Ma; Liya Kong; Xinlong Li; Hepan Zhu; Xin Zhong; Junhai Pan; XianFa Wang
Journal:  J Gastrointest Surg       Date:  2018-05-29       Impact factor: 3.452

2.  Early Gastric Cancer with Mixed-Type Histology: A Mixed Bag or Pure Evil?

Authors:  Mohamed O Othman
Journal:  Dig Dis Sci       Date:  2020-01       Impact factor: 3.199

3.  Lymph node metastasis risk factors and applicability of endoscopic submucosal dissection in mixed-type early gastric cancer in Chinese patients.

Authors:  Pengwei Liu; Lin Li; Jing Wang; Hong Song; Chiyi He
Journal:  J Gastrointest Oncol       Date:  2021-08

4.  Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial.

Authors:  Cas de Jongh; Lianne Triemstra; Arjen van der Veen; Lodewijk A A Brosens; Misha D P Luyer; Jan H M B Stoot; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Gastric Cancer       Date:  2022-09-14       Impact factor: 7.701

Review 5.  Molecular pathogenesis and emerging targets of gastric adenocarcinoma.

Authors:  Abby Ivey; Hillary Pratt; Brian A Boone
Journal:  J Surg Oncol       Date:  2022-06       Impact factor: 2.885

6.  Histological Differentiated/Undifferentiated Mixed Type Should Not Be Considered as a Non-Curative Factor of Endoscopic Resection for Patients With Early Gastric Cancer.

Authors:  Xiaolong Tang; Mengjun Zhang; Qingsi He; Guorui Sun; Chao Wang; Peng Gao; Hui Qu
Journal:  Front Oncol       Date:  2020-09-03       Impact factor: 6.244

7.  Differential analysis of lymph node metastasis in histological mixed-type early gastric carcinoma in the mucosa and submucosa.

Authors:  Qian Zhong; Qi Sun; Gui-Fang Xu; Xiu-Qin Fan; Yuan-Yuan Xu; Fei Liu; Shi-Yi Song; Chun-Yan Peng; Lei Wang
Journal:  World J Gastroenterol       Date:  2018-01-07       Impact factor: 5.742

8.  Long-Term Nutritional Outcomes of Near-Total Gastrectomy in Gastric Cancer Treatment: a Comparison with Total Gastrectomy Using Propensity Score Matching Analysis.

Authors:  Ho Seok Seo; Yoon Ju Jung; Ji Hyun Kim; Cho Hyun Park; In Ho Kim; Han Hong Lee
Journal:  J Gastric Cancer       Date:  2018-06-28       Impact factor: 3.720

9.  Mixed Type Histology as a Predictive Factor for Esophagojejunostomy Leak in Advanced Gastric Cancer.

Authors:  Karol Rawicz-Pruszyński; Katarzyna Sędłak; Radosław Mlak; Jerzy Mielko; Wojciech P Polkowski
Journal:  Cancers (Basel)       Date:  2020-06-26       Impact factor: 6.639

10.  Histopathological validation of magnifying endoscopy for diagnosis of mixed-histological-type early gastric cancer.

Authors:  Yuichiro Ozeki; Kingo Hirasawa; Ryosuke Kobayashi; Chiko Sato; Yoko Tateishi; Atsushi Sawada; Ryosuke Ikeda; Masafumi Nishio; Takehide Fukuchi; Makomo Makazu; Masataka Taguri; Shin Maeda
Journal:  World J Gastroenterol       Date:  2020-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.